Chest high-resolution computed tomography can make higher accurate stages for thoracic sarcoidosis than X-ray

Yuan Zhang1†, Shan-shan Du1†, Meng-meng Zhao1†, Qiu-hong Li1†, Ying Zhou1, Jia-cui Song1, Tao Chen1, Jing-yun Shi2, Bing Jie2, Wei Li2, Li Shen1, Fen Zhang1, Yi-liang Su1, Yang Hu1, Elyse E. Lower3, Robert P. Baughman3 and Huiping Li1*

Abstract

Background: To explore if chest high-resolution computed tomography (HRCT) can make higher accurate stages for thoracic sarcoidosis stage than X-ray (CRX) only.

Methods: Clinical data from medical records of consecutive patients with a confirmed diagnosis of pulmonary sarcoidosis at Shanghai Pulmonary Hospital from January 1, 2012 to December 31, 2016 and consecutive patients treated at the Sarcoidosis Center of University of Cincinnati Medical Center, Ohio, USA from January 1, 2010 to December 31, 2015 were reviewed. The clinical records of 227 patients diagnosed with sarcoidosis (140 Chinese and 87 American) were reviewed. Their sarcoidosis stage was determined by three thoracic radiologists based on CXR and HRCT presentations, respectively. The stage determined from CXR was compared with that determined from HRCT.

Results: Overall, 50.2% patients showed discordant sarcoidosis stage between CXR and HRCT (52.9% in Chinese and 44.8% in American, respectively). The primary reason for inconsistent stage between CXR and HRCT was failure to detect mediastinal lymph node enlargement in the shadow of the heart in CXR (22.1%) and small nodules because of the limited resolution of CXR (56.6%). Stage determined from HRCT negatively correlated with carbon monoxide diffusing capacity (DLCO) significantly (P < .01) but stage determined from CXR did not. Pleural involvement was detected by HRCT in 58 (25.6%) patients but only in 17 patients (7.5%) by CXR. Patients with pleural involvement had significantly lower forced vital capacity and DLCO than patients without it (both P < .05).

Conclusion: Revised staging criteria based on HRCT presentations included 5 stages with subtypes in the presence of pleural involvement were proposed. Thoracic sarcoidosis can be staged more accurately based on chest HRCT presentations than based on CXR presentations. Pleural involvement can be detected more accurately by HRCT.

Keywords: Sarcoidosis, Pulmonary, Chest x-ray, High-resolution computed tomography, Pleural involvement

Background

Abnormal chest imaging presentations are often the primary clinical characteristics of thoracic sarcoidosis. Currently, thoracic sarcoidosis is staged based on chest radiography (Chest X-ray, CXR) presentations following the 1999 American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders guidelines for sarcoidosis,
which describe five stages of CXR presentations [1]. However, the diagnostic accuracy based on CXR presentations is only 50% [1–3].

The resolution of CXR is often too low to accurately detect small lung nodules, thin patchy lesions, and pleural involvement [4, 5]. In addition, CXR may fail to reveal mediastinal lymph node enlargement and pleural involvement that are in the shadow areas of the heart and diaphragm. Chest high-resolution computed tomography (HRCT) has a higher resolution and provides clear views of the pulmonary hilum, mediastinal lymph node, lung, and pleura, and thus has been successfully used to examine interstitial lung diseases (ILD) and small lung lesions [4–6]. Therefore, HRCT overcomes the limitations of CXR and can more accurately stage thoracic sarcoidosis than CXR. Furthermore, sarcoidosis CXR presentations have been found to be inconsistent with clinical stage [7], whereas sarcoidosis lesion characteristics presented on HRCT are consistent with pulmonary functional changes [8]. Despite the apparent benefits of HRCT over CXR, large scale multicenter studies to compare sarcoidosis stage determined based on CXR presentations versus based on HRCT presentations are still lacking. The current study aimed to fill this knowledge gap. Here, we compared sarcoidosis stage determined based on the presentations of the two examinations in 227 patients (140 Chinese and 87 American). Our results suggest that HRCT can more accurately stage thoracic sarcoidosis than CXR.

**Methods**
**Study design**
This was a retrospective observational study. The study protocols were approved by the Institutional Review Boards of Shanghai Pulmonary Hospital (Approval No. k15-189) and University of Cincinnati Medical Center (Approval No. 2013-3320). Clinical data from medical records of consecutive patients with a confirmed diagnosis of pulmonary sarcoidosis at Shanghai Pulmonary Hospital from January 1 2012 to December 31 2016 and consecutive patients treated at the Sarcoidosis Center of University of Cincinnati Medical Center, Ohio, USA from January 1 2010 to December 31 2015 were reviewed. Written consent to participate was obtained from all of the patients. The authors report no conflicts of interest.

**Patient inclusion and exclusion criteria**
The inclusion criteria were: (1) histopathological analysis confirmed that the lesion specimens showed non-caseating epithelioid granuloma; (2) the diagnosis of sarcoidosis was confirmed. The histopathology of lymph node or subcutaneous nodules biopsy of the patients with sarcoidosis was characterized by non-caseous, non-necrotizing granulomas and showed negative TB, fungus and/or parasitic infection, tumor, and vasculitis. Additionally, to further confirm sarcoidosis, smear-negative TB was excluded based on the methods we had established [9, 10]; (3) patients had chest imaging data for at least one HRCT and one CXR, and the time between HRCT and CXR was less than two weeks. Patients with tuberculous, fungal and/or parasitic infections, and/or malignancy were excluded.

**CXR and HRCT evaluation**
Three thoracic radiologists and two pulmonologists independently reviewed patients' imaging data and staged sarcoidosis based on CXR and HRCT characteristics, respectively. Inconsistent staging results among the five specialists were discussed until a consensus was achieved. Sarcoidosis stage determined from CXR presentations was compared with that determined from HRCT presentations.

**Statistical analysis**
The statistical analysis software SPSS 16.0 was used. Measurement variables are presented as mean (standard deviation, SD). Chi-square test was used to compare the differences in sarcoidosis stage of Chinese patients versus American patients. The association between sarcoidosis stage and lung functional parameters were analyzed by bivariate spearman correlation analysis. The difference in lung functional parameters of two patient groups was analyzed by independent t-test. *P* < 0.05 was considered statistically significant.

**Results**
**Comparison of general clinical data of Chinese versus American patients**
Patient selection flow chart is displayed in Fig. 1. A total of 227 subjects including 140 Chinese Han and 87 American patients (W/B, 31/56) with sarcoidosis were included in the analysis. Comparison of the general clinical data revealed significant differences in sarcoidosis stage of the two patient groups (*P* < 0.01, Table 2). Compared with the American patients, Chinese patients had substantially higher proportions of stage I (38.6% vs. 18.4%) and II (40% vs.12.6%) but lower proportion of stage IV (1.4% vs. 41.4%, Table 1). In addition, the Chinese patients showed significantly higher FVC, FVC%, FEV1, FEV1/FVC, DLCO, and DLCO% at the diagnosis (All *P* < 0.01, Table 1) than the American patients, suggesting that the Chinese patients might have better lung function at the diagnosis.
Table 1  Clinical characteristic of 227 patients at the diagnosis

| Characteristics                                      | Chinese (n = 140) | American (n = 87) |
|------------------------------------------------------|------------------|-------------------|
| Mean age ± SD (years)                                | 48.8 ± 8.1       | 43.6 ± 11.7       |
| Men/women                                           | 43/97 (0.44:1)   | 31/56 (0.55:1)    |
| Race                                                 | Han (140)        | Black/White (56/31) |
| Sarcoidosis stage according to chest X-ray presentations$^5$, n (%) |                   |                   |
| 0                                                    | 9 (6.4)          | 7 (8)             |
| I                                                    | 54 (38.6)        | 16 (18.4)         |
| II                                                   | 56 (40)          | 11 (12.6)         |
| III                                                  | 19 (13.6)        | 17 (19.5)         |
| IV                                                   | 2 (1.4)          | 36 (41.4)         |
| Sarcoidosis diagnosis by different approach (n)      |                   |                   |
| EOB                                                  | 48               | 41                |
| Surgery                                              | 83               | 18                |
| Extra lung biopsy                                    | 9                | 28                |
| Pulmonary function tests                             |                   |                   |
| FVC$^5$, mean ± SD (L)                               | 3.0 ± 0.7        | 2.6 ± 0.6         |
| FVC$^5$, predicted, mean ± SD (%)                    | 84.7 ± 10.3      | 760 ± 16.4        |
| FEV1$^5$, mean ± SD (L)                              | 2.4 ± 0.6        | 20 ± 0.6          |
| FEV1/FVC$^5$, mean ± SD                              | 79.9 ± 5.9       | 71.8 ± 12.7       |
| DLCO$^5$, mean ± SD (L)                              | 203 ± 46         | 152 ± 3.8         |
| DLCO$^5$, mean ± SD (%)                              | 92.4 ± 12.2      | 63.9 ± 19.1       |

SD standard deviation, EOB electronic bronchoscope, FVC forced vital capacity, FEV1 forced expiratory volume in one second, DLCO carbon monoxide diffusing capacity. Chi-square test was used for the comparison

$^5 p < 0.01$
Table 2  Comparison of sarcoidosis stage determined according to chest X-ray (CXR) versus chest HRCT presentations

| Stage | Stage according to CXR (n) | Stage according to HRCT (n) | Consistent cases (n) | Consistency rate (%) |
|-------|---------------------------|-----------------------------|----------------------|---------------------|
|       | I  | II | III | IV | I  | II | III | IV |           |               |
| Total | 227 | 16 | 2 | 11 | 3 | 0 | 0 | 0 | 0 | 0.0 |
|       | 140 | 9 | 2 | 7 | 0 | 0 | 0 | 0 | 0 | 0.0 |
|       | 87  | 7 | 0 | 4 | 3 | 0 | 0 | 2 | 12.5 |
| Chinese patients |   |    |   |    |   |   |   |   |   |
|       | 140 | 54 | 6 | 48 | 0 | 0 | 6 | 6 | 11.1 |
|       | 87  | 16 | 2 | 14 | 0 | 0 | 2 | 0 | 12.5 |
|       | 87  | 11 | 0 | 6 | 0 | 0 | 5 | 6 | 54.5 |
|       | 87  | 17 | 0 | 8 | 4 | 5 | 4 | 23.5 |
|       | 87  | 26 | 0 | 36 | 7 | 46 | 48 | 55.2 |

Comparison of sarcoidosis stage determined from CXR presentations versus from HRCT presentations

Sarcoidosis stage determined from CXR and HRCT presentations were not consistent (Table 3). Of the 227 patients, although the 67 patients at stage II and 38 at stage IV showed consistent sarcoidosis stage from the presentations of the two examinations, the consistence rates for the patients at stage 0, I and III were only 0%, 11.4% and 16.7%, respectively. The overall consistent rate in the 227 patients was 50.2% (47.1% in Chinese and 55.2 in American) (Table 2).

Reasons for the inconsistent sarcoidosis stage

We identified four reasons to explain the stage inconsistency from the two examinations (Additional file 2: Table S1). The most common reason in both patient groups was B1, which describes missed lesions by CXR because of the low resolution of CXR (Additional file 2: Table S1). The other reasons included missed lesions by CXR because the lesion imaging signals were masked by the heart and other intrathoracic structure in CXR (Additional file 2: Table S1). Lung fibrosis was not detected by CXR in patients at stage IV.

Patients at stage 0 determined from CXR presentations

Sixteen patients presented respiratory symptoms but showed normal CXR, and thus were diagnosed as stage 0. Two of them presented mediastinal lymph node enlargement on the followed HRCT and were then moved to stage I (Additional file 1: Figure S1A and B), and the other 11 presented mediastinal lymph node enlargement combined with small lung nodules on HRCT and thus were moved to stage II (Additional file 1: Figure S1C, D, and E). Three of them were then moved to stage III based on their HRCT presentations (Additional file 1: Figure S1F and G). The reasons for missing the lesions were the low resolution of CXR and the locations of the lesions in the shadow areas of the heart or other thoracic structures (Additional file 2: Table S1).

Patients at stage I determined from CXR presentations

Only 8 of the 70 patients (11.4%) at stage I determined from their CXR presentations remained at stage I based on their HRCT presentations. The other 62 patients (88.6%) only presented hilar enlargement on CXR, whereas showed additional intrathoracic lymph node enlargement and lung infiltrating opacities on their HRCT. Thus, the 62 patients were moved to stage II.
based on their HRCT presentations. (Additional file 1: Figure S2). These findings indicate that CXR may fail to reveal mild infiltrating lesions in the lung because of its low resolution.

**Patients at stage II determined from CXR presentations**

All the 67 patients at stage II based on CXR remained at stage II when their HRCT presentations were used to determine the stage, suggesting that HRCT could detect all the lesions that can be found by CXR. Notably, the number of patients with stage II determined from HRCT presentations (158 cases) was substantially higher than that based on CXR presentations (67 cases). HRCT may identify lesions that could be missed by CXR and thus patients diagnosed as stage I based on CXR may be moved to stage II or higher when their HRCT presentations were used for sarcoidosis staging. In contrast to the Chinese patients, only 6 (54.5%) of the 11 American patients originally at stage II based on CXR remained at stage II based on HRCT, and the other 5 (45.5%) were moved to stage IV. These results suggest that CXR may not show lung fibrosis as accurately as HRCT.

**Patients at stage III determined from CXR presentations**

Of the 36 patients at stage III based on CXR, 63.9% (23/36) were down staged to sarcoidosis stage II based on HRCT (Table 2) because hilar or mediastinal lymph node enlargement were missed from CXR (Additional file 1: Figure S3). Seven became stage IV based on HRCT because CXR failed to show lung fibrotic lesions.

**Correlation between pulmonary function parameters and sarcoidosis stage**

Sarcoidosis stage determined from HRCT presentations significantly correlated with, FEV1/FVC, carbon monoxide diffusing capacity (DLCO), and DLCO% negatively (All \( P < 0.001 \), Table 3), suggesting that patient pulmonary function may become worse as sarcoidosis progress to higher stage. In contrast to the stage from HRCT presentations, the stage from CXR presentations showed no significant correlation with DLCO and DLCO%.

**Pleural involvement**

Of the total 227 patients, HRCT revealed 58 cases (25.6%) of pleural involvement, whereas CXR only found the condition in 17 cases (7.5%). HRCT revealed that 21.4% of the Chinese patients and 34.5% of the American patients had pleural involvement (Additional file 1: Figure S4), including isolated pleural nodules, isolated pleural thickening, and pleural effusion (Additional file 2: Table S2). For patients at stage II, III, or IV, those with pleural involvement had significantly poorer DLCO% (Fig. 2A) and FVC% (Fig. 2D) than the patients without it (All \( P < 0.05 \)). For the patients at stage IV, those with pleural involvement had significantly lower DLCO% than those without it (\( P = 0.0374 \), Fig. 2B). The patients at stage IV had significantly poorer lung function than the patients at stage II (All \( P < 0.05 \), Fig. 2C and F). Although the mean FVC% of patients at stage IV with pleural involvement was less than that of patients at stage IV without pleural involvement, the difference was not statistically significant (Fig. 2E).

**Discussion**

For more than fifty years, chest x-ray alone has been used to stage the degree of lung involvement [11]. Although the 1999 ATS/ERS/WASOG guidelines do describe that HRCT presentations may be inconsistent with CXR presentations, the staging criteria based on CXR presentations has not been updated because of lacking sufficient clinical evidence. In addition, lung biopsy may identify pulmonary infiltrating lesions in patients with a normal CXR [3, 12]. Moreover, sarcoidosis stage determined from CXR presentations does not correlate with the severity of clinical symptoms and the disease prognosis [7, 8]. Thus, staging sarcoidosis based on CXR presentations may be inadequate in detecting lung involvement.

| Pulmonary functional parameters | Stage by CXR (0/I/II/III/IV) | Stage by HRCT (I/II/III/IV) |
|---------------------------------|------------------------------|----------------------------|
|                                 | Correlation index | \( p \) value | Correlation index | \( p \) value |
| FVC                             | -0.073           | 0.413          | -0.125           | 0.163          |
| FEV1                            | -0.168           | 0.06           | -0.247           | 0.006          |
| FEV1/FVC                         | -0.46            | <0.001         | -0.618           | <0.001         |
| DLCO                            | -0.153           | 0.139          | -0.353           | <0.001         |
| DLCO%                           | -0.182           | 0.096          | -0.380           | <0.001         |

Bivariate spearman correlation analysis was performed.

\( FVC \) forced vital capacity, \( FEV1 \) forced expiratory volume in one second, \( DLCO \) carbon monoxide diffusing capacity.
and thus may not be as informative as HRCT in directing effective therapies for sarcoidosis.

In most of Chinese ILD centers, HRCT is routinely used for the evaluation of all patients presenting with ILD, including sarcoidosis. HRCT is more sensitive than CXR for the detection of mild adenopathy particularly in subcarinal, anterior, and posterior mediastinal regions. Moreover, CT can reveal lung parenchyma abnormalities not seen on CXR. Use of HRCT may suggest additional diagnostic procedures such as transbronchial lung biopsy and endobronchial ultrasound in patients undergoing evaluation for possible sarcoidosis [13].

Therefore, we believe using HRCT to stage thoracic sarcoidosis may be more accurate and could better support sarcoidosis diagnosis and treatment. In our current study, we reviewed the clinical records of 140 Chinese and 87 American patients with sarcoidosis and staged sarcoidosis based on their chest HRCT and CXR presentations, respectively. Our study found that the rate of consistent stage from CXR and HRCT presentations was only 50.2% (47.1% in Chinese and 55.2% in American patients). The primary reason for the inconsistency was that CXR failed to reveal small lesions because of the limited resolution of CXR. Additionally, CXR could also fail to show hilar/mediastinal lymph node enlargement and lesions involving pleura, which are in the shadow areas of the heart and diaphragm. HRCT can clearly overcome these limitations of CXR. Thus, using HRCT to stage sarcoidosis may more accurately reflect the disease status in the lung, pleura, and intrathoracic lymph nodes than using CXR presentations. However, HRCT can't totally replace CXR because of issues related to radiation safety and cost.

**Recommendations for an update of pulmonary sarcoidosis staging criteria**

The current study suggests that staging sarcoidosis based on CXR presentations may not be accurate. HRCT presentations should be included for staging pulmonary sarcoidosis. Pleural involvement may be associated with sarcoidosis prognosis. Thus, we recommend a routine HRCT and use HRCT presentations for staging thoracic sarcoidosis. Here, we propose thoracic sarcoidosis staging criteria based on HRCT presentations included 5 stages as listed in (Table 4). If pleural involvement occurs, the stage is 0’, I’, II’, III’, and IV’.
Compared to the American patients, Chinese patients had substantially higher proportions of stage I and II but lower proportion of stage IV. The Chinese patients presented better pulmonary function at the diagnosis than the American patients, indicating that HRCT may be more widely used in China than in US, and thus more patients with early-stage sarcoidosis could be diagnosed in China.

Zappala and colleagues have suggested that compared with CXR presentations, HRCT presentations appear to be more consistent with pulmonary functional changes [8]. Our current study also showed that sarcoidosis stage determined from HRCT presentations better correlated with pulmonary function parameters than the stage determined from CXR presentations. In particularly, patients with higher disease stage based on HRCT presentations had poorer DLCO and DLCO%, suggesting poorer pulmonary function in these patients. These means the new staging system based on HRCT presentations might recognize severe sarcoidosis patients with poorer prognosis.

Sarcoidosis involving pleura, which usually presents pleural thickening, small pleural nodules, pleural effusion, pneumothorax, chylothorax, and/or hemothorax, has been considered rare for a while [1–3]. In 2005, Szwarcberg and colleagues reported that HRCT identified 25 cases (41%) of pleural involvement in 61 cases of sarcoidosis but CXR only identified 7 cases (11%) [14]. Use of HRCT seems more sensitive than ultrasound in detecting pleural effusion in sarcoidosis [15, 16]. Wang et al. [17] searched the literature databases and found 28 articles which reported 92 cases of sarcoidosis with pleural involvement, including 59 cases of pleural effusion, 29 pleural thickening, 3 pneumothorax, and one pleural nodules. Our current study demonstrated that HRCT identified 58 cases of pleural involvement (58/227, 25.6%) whereas CXR only revealed 17 (17/227, 7.5%). The top three common types of pleural involvement in our study were pleural thickening (26 cases, 11.5%), pleural nodules (18 cases, 7.9%), and pleural effusion (9 cases, 4.0%) that was similar to Huggins’s report (2.8%) [13]. We also found the proportion of pleural involvement in patients with stage IV sarcoidosis increased substantially (23/50, 46%) and patients with pleural involvement (particularly for patients with stage IV) had poorer FVC and DLCO% than patients without it. However, the current sarcoidosis staging criteria does not describe pleural involvement. HRCT can detect pleural involvement more accurately than CXR. Thus, we believe it is necessary to include the presence of pleural involvement as a subtype in thoracic sarcoidosis staging criteria.

Conclusion
Revised staging criteria based on HRCT presentations included 5 stages with subtypes in the presence of pleural involvement were proposed. Sarcoidosis stage determined based on HRCT presentations appeared to be more accurate than the stage determined from CXR presentations, and can detect different types of pleural involvements. Sarcoidosis with pleural involvement was associated with worse pulmonary diffusion function.

Abbreviations
HRCT: High-resolution computed tomography; CXR: Chest X-ray; ILD: Interstitial lung diseases; TB: Tuberculosis.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12890-022-01942-y.

### Table 4 Sarcoidosis staging criteria based on chest HRCT presentation

| Stage | Chest X-ray and HRCT presentations | With pleural involvement |
|-------|------------------------------------|--------------------------|
| 0     | No abnormal presentation           | 0*                      |
| I     | Bilateral hilar and/or mediastinal lymph node enlargement and without lung infiltration opacities | I*                      |
| II    | Bilateral hilar and/or mediastinal lymph node enlargement and with reticular, nodular, and patchy opacities | II*                     |
| III   | Reticular, nodular, and/or patchy opacities and without bilateral hilar and/or mediastinal lymph node enlargement | III*                    |
| IV    | Pulmonary fibrosis, honeycomb lung, pulmonary bulla, and emphysema | IV*                     |

*stands for with pleural involvement

Additional file 1. Figures S1–S4. Figure S1. Chest X-ray and HRCT images of 3 patients diagnosed as sarcoidosis stage 0 by chest X-ray but stage I, II, and III, respectively, by HRCT presentations. Figure S2. Chest X-ray and HRCT images of one patient diagnosed as sarcoidosis stage I by X-ray and stage II by HRCT presentations. Figure S3. Chest X-ray and HRCT images of one patient diagnosed as sarcoidosis stage III by chest X-ray and stage II by HRCT presentations. Figure S4. HRCT images of one patient showing pleural involvement. A. Pleural nodules.

Additional file 2. Tables S1 and S2. Table S1. Reasons for the inconsistent stage determined according to CXR and HRCT presentations. Table S2. Pleural involvement in the patients.
Acknowledgements
The authors thank Dr. Y. Huang (The Center of Thyroid diseases, the Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai, China) and X. Wang (Dept. of Preventive Medicine, Inner Mongolia Medical School, Inner Mongolia, China) for their helpful discussions in statistical analysis. We also thank all of our patients’ cooperation and all of author’s work.

Author contributions
Experimental design: H.P.L., Y.Z., S.S.D., M.M.Z.; Data acquisition and analysis: Y.Z., S.S.D., Q.H.L.; Writing the manuscript: Y.Z. and H.P.L. All authors read and approved the final manuscript.

Funding
This study was funded by the National Natural Science Foundation of China (No: 81500052, 81730002, 81670055, 81670056, 91442103 and 81570057), Ministry of Science and Technology of the People’s Republic of China (2016YFC1102000, 2016YFC1102004), National Natural Science Foundation of Shanghai (18ZR1431400), Shanghai Family Planning Commission Health Industry Clinical Research Project (2020YQ0383), and Shanghai Hospital Development Center (16CR0354A).

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
The study protocol was approved by the Institutional Review Boards of Shanghai Pulmonary Hospital (Approval No.K15-189) and University of Cincinnati Medical Center (Approval No. 2013-3320), all methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all subjects and/or their legal guardian(s).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Respiratory Medicine, School of Medicine, Shanghai Pulmonary Hospital, Tongji University, 507 Zheng Min Road, Shanghai 200043, China. 2Department of Radiology, School of Medicine, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China. 3Department of Internal Medicine, University of Cincinnati Medical Center, 1001 Holmes, 200 Albert Sabin Way, Cincinnati, OH 45267, USA.

Received: 3 November 2021 Accepted: 5 April 2022
Published online: 16 April 2022

References
1. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasculitis Diffuse Lung Dis. 1999;16(2):149–73. Epub 1999/11/24.
2. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011;305(4):391–9. Epub 2011/01/27. https://doi.org/10.1001/jama.2011.10.
3. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183(5):573–81. Epub 2010/11/03. https://doi.org/10.1164/rccm.201006-0865CI.
4. Hartley PG, Galvin JR, Hunninghake GW, Merchant JA, Yagla SJ, Speakman SB, et al. High-resolution CT-derived measures of lung density are valid indexes of interstitial lung disease. J Appl Physiol. (Bethesda, Md : 1985). 1994;76(1):271–7. Epub 1994/01/01. https://doi.org/10.1152/jappl.1994.76.1.271.
5. Sundaram B, Chugharai AR, Kazerooni EA. Multidetector high-resolution computed tomography of the lungs: protocols and applications. J Thoracic Imaging. 2010;25(2):125–41. Epub 2010/05/14. https://doi.org/10.1097/RTI.0b013e3181f9da37.
6. Aziz ZA, Wells AU, Hansell DM, Bain GA, Copley SJ, Desai SR, et al. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax. 2004;59(6):506–11. Epub 2004/06/01. https://doi.org/10.1136/thx.2003.020396.
7. Zappala CJ, Desai SR, Copley SJ, Spagnolo R, Cramer D, Sen D, et al. Optimal scoring of serial change on chest radiography in sarcoidosis. Sarcoidosis Vasculitis Diffuse Lung Dis. 2011;28(2):130–8 (Epub 2011/11/29).
8. Zappala CJ, Desai SR, Copley SJ, Spagnolo R, Sen D, Alam SM, et al. Accuracy of individual variables in the monitoring of long-term change in pulmonary sarcoidosis as judged by serial high-resolution CT scan data. Chest. 2014;145(1):101–7. Epub 2013/09/21. https://doi.org/10.1378/chest.12-2479.
9. Zhou Y, Li HP, Li QH, Zheng H, Zhang RX, Chen G, et al. Differentiation of sarcoidosis from tuberculosis using real-time PCR assay for the detection and quantification of Mycobacterium tuberculosis. Sarcoidosis Vasculitis Diffuse Lung Dis. 2008;25(2):93–9 (Epub 2009/04/23).
10. Li QH, Li HP, Shen YP, Zhao L, Shen L, Zhang Y, et al. A novel multi-parameter scoring system for distinguishing sarcoidosis from sputum negative tuberculosis. Sarcoidosis Vasculitis Diffuse Lung Diseases. 2012;29(1):11–8 (Epub 2013/01/15).
11. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. British medical journal. 1961;2(5261):1165–72. Epub 1961/11/04. https://doi.org/10.1136/bmj.2.5261.1165.
12. de Boer S, Milne DG, Zeng I, Wilsher ML. Does CT scanning predict the likelihood of a positive transbronchial biopsy in sarcoidosis? Thorax. 2009;64(5):436–9. Epub 2009/02/14. https://doi.org/10.1136/thx.2008.105031.
13. Zhou Y, Lower EE, Li H, Baughman RP. Clinical management of pulmonary sarcoidosis. Expert Rev Respir Med. 2016;10(5):577–91. Epub 2016/03/10. https://doi.org/10.1586/17476348.2016.1164602.
14. Szwarzberg JB, Glajchen N, Teirstein AS. Pleural involvement in chronic sarcoidosis detected by thoracic CT scanning. Sarcoidosis Vasculitis Diffuse Lung Diseases. 2005;22(1):58–62 (Epub 2005/05/11).
15. Huggins JT, Doelken P, Sahn SA, King L, Judson MA. Pleural effusions in a series of 181 outpatients with sarcoidosis. Chest. 2006;129(6):1599–604. Epub 2006/06/17. https://doi.org/10.1378/chest.129.6.1599.
16. Rivera E, Gesthalten Y, Vardelaan P, Chee A, Majid A. Sarcoidosis with pleural effusion as the presenting symptom. J Bronchol Interventional Pulmonol. 2018;25(2):148–51. Epub 2018/01/19. https://doi.org/10.1097/LBR.0000000000000453.
17. Wang F, Tong Z, Wang Z, Wang X, Xu L. Sarcoidosis related pleural effusion: 6 case reports and literature review. Chin J Tuberculosis Respir Dis.. 2015;38(2):99–104. Epub 2015/04/25.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.